RoosterBio Inc.

Scalable #extracellularvesicle (EV) purification requires complex equipment, expertise, and investment in process development. Take advantage of RoosterBio’s optimized EV downstream processing solutions instead with QuickShip™ DSP, and achieve higher EV yields faster. Learn more and request your QuickShip DSP price here.➡️ https://lnkd.in/e8aTQRPT #extracellularvesicles #exosome #exosomes #downstreamprocessing #advancedtherapies #bioprocessing

Congratulations to the following 3 Value Award winners! These Roosters were nominated by their peers for going above and beyond to exemplify RoosterBio's core values: 🤝 Christina Jenkins' dedication to #CustomerFocus is clear. She is committed to making sure that our customers get the highest quality, graciously accommodates last minute requests, and makes sure that the customer is happy. 🎖️ Matthew Rehmann demonstrates #Integrity in every facet of project management. Understanding the status of our technologies, programs, and bandwidth is critical. He provides accurate descriptions with a keen eye towards technical and commercial success. 🥼 Megan Brittain goes above and beyond to support her team. When training, Megan dedicates time to shadow each team member and make sure things are going well. We appreciate Megan’s #Teamwork and dedication to making sure all projects are executed smoothly.

📘 In the last decade, biotechnology has been quietly perfecting the infrastructure to rapidly “amp up” advanced therapy bioprocesses. RoosterBio’s AgentV™-DSP is one of many innovations that is "changing the tune” for cell therapies and bioproduction, offering 10-fold greater efficiency for MSC-derived exosome manufacturing. Our latest blog and accompanying webinar detail how this downstream processing treatment can help you significantly improve exosome yield while maintaining quality. Read it here: https://lnkd.in/eK4eVhaq #exosomes #extracellularvesicles #bioprocessing #biomanufacturing #celltherapymanufacturing #microvesicles #advancedtherapies

https://lnkd.in/efvZkUvh ⬅️ This bioRxiv preprint by Dr. Ross Marklein and colleagues at FDA-CDER and The University of Georgia explores how mesenchymal stromal cell-derived #extracellularvesicles (MSC-EVs) might one day help treat neurodegenerative diseases by modulating brain pericytes, key players in blood-brain barrier integrity and inflammation. They developed a novel method to assess pericyte shape changes, while showing that MSC-EVs could down-regulate hallmarks of neuroinflammation. RoosterBio is proud to support this important research via its MSCs, bioprocess expertise, and high-performance culture media. #neurodegenerativedisease #inflammation #celltherapy #exosomes #celltherapyresearch #regenerativemedicine #stemcelltherapy #stromalcells

As published in Nature Communications, scientists at SHIFTBIO INC. in collaboration with RoosterBio developed SIRP-EVs (engineered mesenchymal stem cell-derived vesicles) as a new treatment for ALF (acute liver failure). This publication highlights the scalable 3D #bioreactor process developed to manufacture high yields of SIRP-EVs coupled with an effective downstream process that concentrates EVs and removes impurities. MSC-derived SIRP-EVs outperform HEK cell-derived versions, highlighting their unique therapeutic potential. RoosterBio is proud to support this groundbreaking research and is especially privileged to play a part in these exciting and ongoing preclinical advances with ShiftBio's innovative team. Read it here: https://lnkd.in/gWG_T6rV #extracellularvesicles #exosomes #stemcellresearch #celltherapy #regenerativemedicine #advancedtherapy #liverfailure #molecularmedicine #bioprocessing

RoosterBio's QuickShip™ hMSCs are human mesenchymal stromal/stem cell banks manufactured from your selected tissue and donor using highly consistent and reproducible MSC production systems. Whether you need millions or billions of cells, spend less time deriving and culturing cell banks and more time generating data with confidence in your study's reproducibility. Request a quote here ➡️ https://lnkd.in/dGBD8ijG #celltherapymanufacturing #celltherapy #stemcelltherapy #stemcells #stromalcells #mesenchymalstemcells

Looking ahead, rigorous characterization is what will allow extracellular vesicle-based discoveries to move toward clinical applications with clarity and credibility. #MISEV offers consensus-driven recommendations that enable researchers to design robust experiments, interpret results confidently, and ensure reproducibility. Learn more about "the spirit of MISEV" in our latest blog. ➡️ https://lnkd.in/ed7iVa3d #extracellularvesicles #exosomes #celltherapy #celltherapymanufacturing #microvesicles #advancedtherapies

In the past decade, extracellular vesicles/exosomes have shown promise for treatment of a variety of diseases and moved into the clinic with dozens of reported clinical trials globally. As the number of clinical trials increases, exosome production requires robust, scalable, and cost-effective processes. In this collaborative study with Cytiva, RoosterBio developed process parameters that can be tailored for a wide variety of therapeutic exosome programs and allows for maximum exosome recovery while maintaining quality. ➡️ Download it here: https://lnkd.in/ez7_QTvH #exosomes #extracellularvesicles #whitepaper #appnote #scalablemanufacturing #bioprocess #bioprocessdevelopment #advancedtherapies #stemcells

This blog post explores chimeric antigen receptors displayed on #exosomes and extracellular vesicles (EV-CARs) that could offer a cell-free, scalable alternative to CAR-T therapies. This modality promises fewer side effects like #cytokine release syndrome, superior penetration of solid tumors, and #bioproduction from abundant and standardized allogeneic cell sources. Though still in early development, EV-CAR technology shows potential to revolutionize cancer treatment and more in a few years. 🔗 https://lnkd.in/eTZt44Ph #extracellularvesicles #antigen #cart #tcell #immunotherapies #cancerresearch #geneticengineering

📑 This study led by McGill University's Professor Lisbet Haglund, analyzed #extracellularvesicles (EVs) from intervertebral disc (IVD) cells across tissue degeneration grades. Proteomic analysis revealed 88.6% of EV proteins were shared, but their abundance varied. That is, mildly-degenerate EVs had distinct extracellular matrix-related cargo. Enabled in part by RoosterBio's EV collection medium (RoosterCollect™-EV), these findings shed light on IVD degeneration mechanisms, suggesting biomarkers and therapeutic targets for low back pain. Read more: https://lnkd.in/e5_3CqDh #exosomes #lowerbackpain #microvesicles #biomarkers #nanoparticle #chromatography #westernblot #celltherapy